

STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

Docket No.
14102-1US

In Re Application Of: ESCHER, Alan P. et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/523,655	February 4, 2005	To be assigned	23676	1632	3703

Invention: SUBSTANCES FOR PREVENTING AND TREATING AUTOIMMUNE DISEASES



COMMISSIONER FOR PATENTS:

This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application.

Check applicable statement herebelow:

Statement Under 37 CFR 1.97(e)(1)

- ☒ Each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

Statement Under 37 CFR 1.97(e)(2)

- ☐ No item of information contained in the accompanying Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Signature

David A. Farah, M.D.
SHELDON & MAK PC
225 South Lake Avenue, 9th Floor
Pasadena, California 91101
Tel.: (626) 796-4000
Fax: (626) 795-6321
E-mail: davidf@usip.com

Dated: February 2, 2006

Certificate of Mailing by First Class Mail

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

February 2, 2006

(Date)

Signature of Person Mailing Correspondence

Marilyn Paik


Typed or Printed Name of Person Mailing Correspondence

cc: Loma Linda University

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>	Docket Number (Optional) 14102-1US	Application Number 10/523,655
	Applicant(s) ESCHER, Alan P. et al.	
	Filing Date February 4, 2005	Group Art Unit 1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE



U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
	C1	European Search Report	11/29/2005	Europe				

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	D1	CONTRERAS, JUAN L. ET AL., "Cytoprotection of pancreatic islets before and early after transplantation using gene therapy." <i>Kidney International</i> , Jan. 2002, Vol. 61, No. 1 Suppl., pp. 79-84
	D2	CONTRERAS, JUAN L. ET AL., Gene transfer of the Bcl-2 gene confers cytoprotection to isolated adult porcine pancreatic islets exposed to xenoreactive antibodies and complement." <i>Surgery</i> . Aug. 2001, Vol. 130, No. 2, pp. 166-174

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.